These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21859377)

  • 1. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences.
    Komura H; Iwaki M
    Drug Metab Rev; 2011 Nov; 43(4):476-98. PubMed ID: 21859377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.
    Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
    Drug Metab Dispos; 2010 Nov; 38(11):1967-75. PubMed ID: 20702772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates.
    Komura H; Iwaki M
    J Pharm Sci; 2008 May; 97(5):1775-800. PubMed ID: 17853429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data.
    Nishimuta H; Sato K; Yabuki M; Komuro S
    Drug Metab Pharmacokinet; 2011; 26(6):592-601. PubMed ID: 21878741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10.
    Mizuma T
    Int J Pharm; 2009 Aug; 378(1-2):140-1. PubMed ID: 19486934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine.
    Martignoni M; Groothuis G; de Kanter R
    Drug Metab Dispos; 2006 Jun; 34(6):1047-54. PubMed ID: 16565172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1/7 variants.
    Ishii Y; Koba H; Kinoshita K; Oizaki T; Iwamoto Y; Takeda S; Miyauchi Y; Nishimura Y; Egoshi N; Taura F; Morimoto S; Ikushiro S; Nagata K; Yamazoe Y; Mackenzie PI; Yamada H
    Drug Metab Dispos; 2014 Feb; 42(2):229-38. PubMed ID: 24255116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
    Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
    Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys.
    Furukawa T; Naritomi Y; Tetsuka K; Nakamori F; Moriguchi H; Yamano K; Terashita S; Tabata K; Teramura T
    Xenobiotica; 2014 Mar; 44(3):205-16. PubMed ID: 23962030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
    Naritomi Y; Nakamori F; Furukawa T; Tabata K
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats.
    Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
    Pharm Res; 2015 Feb; 32(2):604-16. PubMed ID: 25163980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Method for predicting human intestinal first-pass metabolism of UGT substrate compounds.
    Furukawa T; Yamano K; Naritomi Y; Tanaka K; Terashita S; Teramura T
    Xenobiotica; 2012 Oct; 42(10):980-8. PubMed ID: 22540538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baicalin pharmacokinetic profile of absorption process using novel in-vitro model: cytochrome P450 3A4-induced Caco-2 cell monolayers combined with rat intestinal rinse fluids.
    Morisaki T; Hou XL; Takahashi K; Takahashi K
    J Pharm Pharmacol; 2013 Oct; 65(10):1526-35. PubMed ID: 24028620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of capravirine as a CYP3A probe substrate: in vitro and in vivo metabolism of capravirine in rats and dogs.
    Bu HZ; Zhao P; Kang P; Pool WF; Wu EY; Shetty BV
    Drug Metab Dispos; 2007 Sep; 35(9):1593-602. PubMed ID: 17567732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
    Hirunpanich V; Murakoso K; Sato H
    Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.
    Heikkinen AT; Baneyx G; Caruso A; Parrott N
    Eur J Pharm Sci; 2012 Sep; 47(2):375-86. PubMed ID: 22759901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
    Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
    Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.